JAKARTA - The Coordinating Minister for the Economy, Airlangga Hartarto, said that the Food and Drug Administration (BPOM) will issue an Emergency Use Authorization (EUA) permit for the Sinovac vaccine in early 2021.
Airlangga said, currently BPOM will soon get the results of research conducted by Brazil regarding the final stage trial of a vaccine from a pharmaceutical company from China, with the name CoronaVac.
Airlangga said, BPOM is also completing the clinical trial data for the first and second vaccines.
"Then also complete the report from the clinical trial results in Bandung. So that later they will be compiled (combined) by the POM scientifically and we hope that in January (2021) Emergency Use can be given," he said, in a video conference in Jakarta, Thursday, 24 December.
The chairman of the Committee for Handling COVID-19 and National Economic Recovery (KPC-PEN) said the government had decided to allow other types of COVID-19 vaccines besides Sinovac to be given to the public next year.
Meanwhile, the vaccines in question are Pfizer-BioNTech, Moderna, and AstraZeneca.
"(Giving) this vaccine is according to the schedule that can be given to us. This vaccination is a priority for the government and now we are preparing the details," he said.
According to Airlangga, next year's vaccination program will be a big homework or homework that must be implemented properly and measured. With the presence of the COVID-19 vaccine, it is hoped that it can revive the national economy.
"Vaccination is our homework and at the same time a game changer in the economic recovery that will come," he said.
The English, Chinese, Japanese, Arabic, and French versions are automatically generated by the AI. So there may still be inaccuracies in translating, please always see Indonesian as our main language. (system supported by DigitalSiber.id)
